Journal Article Review Epublish
PubMed: 40282933 DOI: 10.3390/medicina61040644
HER2-Low Breast Cancer-Current Knowledge and Future Directions.
Medicina (Kaunas) 61(4)
Authors: Abeer M Shaaban, Tanvier Kaur, Elena Provenzano
Affiliations
- Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK.
- Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
- Department of Cellular Pathology, New Cross Hospital, Wolverhampton WV10 0QP, UK.
- Department of Histopathology, Addenbrookes Hospital, Cambridge CB2 0QQ, UK.
- NIHR Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK.
Abstract
The concept of binary classification of HER2 status has recently been challenged following the DESTINY-Breast trial data showing a clinically meaningful response to antibody-drug conjugates (ADCs) in invasive breast cancer expressing low levels of HER2. HER2-low breast cancer is defined as an immunohistochemistry (IHC) score of 1+ and 2+ without HER2 gene amplification. While HER2-low breast cancer does not represent a biological entity, it encompasses both hormone receptor-positive and triple-negative breast cancer. Differences exist between this group and HER2-null breast cancer. In this review, we provide an update on HER2-low and HER2-ultralow breast cancer, including background trial data, the evolution of HER2-low expression, current clinical guidelines, quality issues, and future directions.
MeSH
Breast Neoplasms, Neoplasms, Breast, Artificial Intelligence